EUVIMEDEUVIMED entdecken
Crossref

Result reporting and early discontinuation of sepsis trials registered on ClinicalTrials.gov

Handan Hu iD, Xinyi Wang, Peng Huang

Journal of Evidence-Based Medicine · 2023-06 · 16 (2) · 186-193

DOI: 10.1111/jebm.12543 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Evidence-Based Medicine, online erschienen am 02.07.2023. Verfasst von Handan Hu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Queen Mary School, Nanchang University, Nanchang, P. R. China. Hauptthemen laut MEDLINE: Research Design, Sepsis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Sepsis is a leading cause of death from infectious disease or traumatic injury. The prevalence and predictor of results underreporting and early stop of sepsis clinical trials remain poorly studied. To fill the gap, we designed this study to characterize sepsis clinical trials registered on ClinicalTrials.gov, particularly to recognize features related to premature discontinuation and lack of results reporting.

Methods

We searched ClinicalTrials.gov to include interventional sepsis trials up to July 8, 2022. All structured data of the identified trials were extracted and reviewed. A descriptive analysis was conducted. Cox and logistic regression analyses were conducted to determine the significance of the association of trial characteristics with early termination and lack of results reporting.

Results

A total of 1654 records were identified, among which 1061 eligible trials were reserved. Results underreporting happened in 91.6% of these sepsis interventional trials. 12.0% were discontinued. Moreover, factors that led to the higher risk of discontinuation were the US‐registered clinical research and the small sample size. The factor that contributed to results underreporting was non‐US‐registered clinical trials.

Conclusion

The frequent discontinuation and underreporting of sepsis trials have highly impaired the progress of sepsis management and studies. Therefore, solutions to early discontinuation and improving the quality of results dissemination remain an urgent problem.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Research DesignSepsisHumansSample SizeClinical Trials as Topic

Stichwörter der Autor:innen

ClinicalTrials.govearly discontinuationresults reportingsepsis

Autor:innen und Institutionen

  • Queen Mary School, Nanchang University, Nanchang, P. R. China.
  • Chinese Evidence-Based Medicine Center, West China Hospital, Chengdu, P. R. China.
  • Center for Evidence-Based Medicine, School of Public Health, Nanchang University, Nanchang, Jiangxi, P. R. China.
  • Jiangxi Province Key Laboratory of Preventive Medicine, School of Public Health, Nanchang University, Nanchang, P. R. China.

ORCID-Profile: Handan Hu

Zitieren

APA

Hu, H., Wang, X., & Huang, P. (2023). Result reporting and early discontinuation of sepsis trials registered on ClinicalTrials.gov. Journal of Evidence-Based Medicine, 16(2), 186-193. https://doi.org/10.1111/jebm.12543

Vancouver

Hu H, Wang X, Huang P. Result reporting and early discontinuation of sepsis trials registered on ClinicalTrials.gov. Journal of Evidence-Based Medicine. 2023;16(2):186-193. doi:10.1111/jebm.12543

BibTeX
@article{Hu2023,
  author = {Hu, Handan and Wang, Xinyi and Huang, Peng},
  title = {Result reporting and early discontinuation of sepsis trials registered on ClinicalTrials.gov},
  journal = {Journal of Evidence-Based Medicine},
  year = {2023},
  volume = {16},
  number = {2},
  pages = {186--193},
  doi = {10.1111/jebm.12543}
}
Kostenlos starten →